Novartis/Idenix Tyzeka To Launch Within 30 Days For Treatment Of Hepatitis B
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis and Idenix will co-promote telbivudine with separate field forces in the U.S.
You may also be interested in...
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Idenix Restructures Under Amended Deal With Novartis
Novartis will take over development, manufacture and commercialization of chronic hepatitis B therapy Tyzeka/Sebivo, pay worldwide royalties to Idenix.